Work

Pos0315 Long-term Safety and Efficacy of Lenabasum During 3 Years in an Open-label Extension (ole) of a Phase 2 Study of Lenabasum in Refractory Skin Disease in Dermatomyositis (dm)

Year: 2021

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2021-eular.2048

Authors: V Werth, J. Concha, J. Burroughs, J. Okawa, R. Feng, A. Jobanputra, R. Borucki, K. Hally, E. Hejazi, M. Tillinger, S. Constantine, N. Dgetluck, B. White

Institutions: University of Pennsylvania, Corbus Pharmaceuticals (United States)

Language: English

Topic: Inflammatory Myopathies and Dermatomyositis

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3165654241

Cites:

Cited by: 2

Related to: 10